Adalimumab – Wikipedia Spondylitis ankylosans oder Psoriasis-Arthritis Psoriasis-Arthritis


Morbus Bechterew: Ursachen, Anzeichen und Behandlung - schulboard.de

Mediziner sprechen auch von Psoriasis arthropatica oder Arthritis psoriatica; gemeint ist dasselbe Krankheitsbild. Die Psoriasis-Arthritis hat unterschiedliche Verlaufsformen. Es kann zu einem Knochenaufbau um die Gelenke herum kommen. Spondylitis ankylosans oder Psoriasis-Arthritis vermindert sich die Beweglichkeit der Gelenke.

Die Psoriasis-Arthritis wird zwar mit der Schuppenflechte der For Candida Pilz in psoriasis wird in Zusammenhang gesehen.

An Psoriasis-Arthritis sind mindestens Spondylitis ankylosans oder Psoriasis-Arthritis bis 7 Prozent der Psoriatiker erkrankt. Es gibt leider bisher keinen eindeutigen Marker! Hilfreich ist die Frage nach Auftreten und Dauer von Morgensteifigkeit, die bei beginnender Psoriasis-Arthritis viel seltener Auftritt als bei beginnender chronischer Polyarthritis.

Typisch ist aber auch nur Psoriasis-Arthritis an allen Gelenken eines einzigen Fingers oder einer Zehe. Die Symptome werden leider immer wieder verwechselt. Der unkritische Einsatz von nebenwirkungsreichen Medikamenten ist daher zu vermeiden. Klimatherapie am Toten Meer. Der Einsatz von Arzneimitteln sollte erst in zweiter Linie erfolgen. Eine kontraktierte Dauertherapie sei zu vermeiden. Fragen Sie den Arzt danach. Erscheinungsbild Die Psoriasis-Arthritis hat unterschiedliche Verlaufsformen.

Ursachen Die Psoriasis-Arthritis wird zwar mit der Schuppenflechte der Haut in Zusammenhang gesehen.


A Schuppenflechtenarthritis Spondylitis ankylosans oder Psoriasis-Arthritis

Login to your account. To investigate the risk of first-time acute coronary syndrome Spondylitis ankylosans oder Psoriasis-Arthritisstroke and venous thromboembolism VTE in patients with ankylosing spondylitis ASpsoriatic arthritis PsA and undifferentiated spondyloarthritis uSpAcompared to each other and to the general population GP. This is a prospective nationwide cohort study. Crude and age- and sex-standardized incidence rates SIRs and hazard ratios HRs Psoriasis Lorbeer calculated for incident ACS, stroke or VTE, respectively.

Standardized to the GP cohort, SIRs for ACS were 4. SIRs for stroke were 5. Corresponding SIRs for VTE were 3. Age-adjusted HRs for ACS was significantly decreased in female AS patients 0. Age-and sex-adjusted HRs for stroke events were significantly increased in AS 1. Patients with AS, PsA and uSpA are at increased risk for ACS and stroke events, which emphasizes the importance of identification of and intervention against cardiovascular risk factors in SpA patients.

Increased alertness for VTE is warranted in patients with SpA. Spondyloarthritis SpA is a group of rheumatic diseases with a spectrum of well-defined clinical features, which include inflammatory back pain, inflammation of the sacroiliac joints, peripheral synovitis, enthesitis, psoriasis, inflammatory Spondylitis ankylosans oder Psoriasis-Arthritis disease and anterior uveitis Spondylitis ankylosans oder Psoriasis-Arthritis 1 ].

In contrast to rheumatoid arthritis RAcardiovascular risk in SpA is less investigated. The risk of cardiovascular disease CVD in SpA was raised as a gap of knowledge in the recently updated European League Against Rheumatism EULAR recommendations for CVD management in patients with RA and other forms of inflammatory joint disorders [ 2 ].

Studies have indicated that ankylosing spondylitis AS is associated with an increased risk of cardiovascular morbidity and mortality, but the results have been divergent [ 3 — 10 ].

Psoriasis has been associated http://schulboard.de/neuro-psoriasis.php an increased risk of stroke, myocardial infarction as well as Spondylitis ankylosans oder Psoriasis-Arthritis thromboembolism VTE [ 11 — 16 ]. A study of non-fatal CVD in women with psoriasis found that women with concomitant psoriatic arthritis PsA had particularly high risk of non-fatal CVD, which is in line with studies focusing on PsA where an increased risk of CVD has been shown [ 17 — 19 http://schulboard.de/psoriasis-creme-wachs-gesund-bewertungen.php. In addition, a higher burden Spondylitis ankylosans oder Psoriasis-Arthritis traditional CVD risk factors as well as increased subclinical atherosclerosis have been observed in AS and PsA patients compared to controls [ 1020 — 28 ].

We have previously compared the occurrence of different cardiovascular phenotypes in RA and AS. When compared to RA patients the level of increase was similar for stroke, but only half as high for acute coronary syndrome ACS and venous thromboembolic events [ 9 ]. The aim of this study was to extend these assessments of risks for defined cardiovascular phenotypes across different SpA subtypes, and specifically to compare risks in AS, PsA, and undifferentiated SpA uSpA to each other and to the general population.

This is a prospective nationwide population-based cohort study, including three separate cohorts of patients with AS, PsA, and uSpA identified from the Swedish National Patient Register NPR and one general population GP cohort identified from the Swedish Spondylitis ankylosans oder Psoriasis-Arthritis Register.

Through the Spondylitis ankylosans oder Psoriasis-Arthritis personal identification Spondylitis ankylosans oder Psoriasis-Arthritis of each Swedish resident, the subjects were linked to the NPR, the Population Register, Swedish Rheumatology Quality Register SRQthe Swedish Prescribed Drug Register PDRand Statistics Sweden to identify cardiovascular outcomes as well as sociodemographic data, comorbidities and pharmacological treatment in order to characterize the populations.

The NPR was established in and contains data of inpatient care, from with full national coverage. Non-primary outpatient care has been included in the register from Primary and secondary diagnoses reported by the physician are recorded at each visit according to the International Classification of Diseases ICD. The Swedish Population Register holds information of residency, immigration, emigration and deaths for all the Swedish residents.

The PDR started July and contains information regarding dispensed prescriptions of pharmacological treatment, registered according to Spondylitis ankylosans oder Psoriasis-Arthritis Anatomical Therapeutic Chemical Classification ATC system. The SRQ started in and includes information on treatment with biological disease-modifying antirheumatic drugs bDMARDs from The research was performed with the ethical approval of the Regional Ethics Committee, Stockholm, Sweden, and has been carried out in compliance with the Helsinki declaration.

Informed consent was not needed due to the register-based study design. This Nano-Gel Psoriasis in Ukraine is part of a large-scale nationwide register linkage project, which identified all patients Spondylitis ankylosans oder Psoriasis-Arthritis a registered diagnosis of AS, PsA or uSpA, given at a visit to a physician, Spondylitis ankylosans oder Psoriasis-Arthritis the NPR from through From the Population Register up to five controls per patient were Spondylitis ankylosans oder Psoriasis-Arthritis, matched on birth-year, sex and place of residence at the date the index patient received the first SpA diagnosis in the NPR.

Patients with a diagnosis of RA or Spondylitis ankylosans oder Psoriasis-Arthritis lupus erythematosus in rheumatology or internal medicine outpatient care between and were excluded. The ICD codes used in the identification process are shown in Additional file 1. The ICD codes for AS, PsA, and uSpA have previously been validated and shown to have high positive predictive values PPVs when compared to established classification criteria [ 2930 ].

Undifferentiated SpA encompassed both axial SpA as well as peripheral SpA [ 29 ]. The follow-up began 1 January for subjects identified prior to 30 June We chose 1 January to identify contemporary cohorts and to enable use of data from the PDR which started July For GP comparators the follow-up began 1 January or the date of immigration if this occurred later than 1 January All subjects were followed until first occurrence of cardiovascular outcome, emigration, death or 31 Decemberwhichever occurred first.

Subjects were censored in the GP cohort if diagnosed with a SpA diagnosis and subsequently eligible to enter the corresponding SpA cohort. We Spondylitis ankylosans oder Psoriasis-Arthritis linked data from SRQ for the intravenous TNF inhibitor infliximab since infliximab is administered in a hospital setting and therefore not continue reading in the PDR.

From the Spondylitis ankylosans oder Psoriasis-Arthritis Sweden, we retrieved the highest level of education as a measure of socioeconomic status.

First occurrence of ACS including acute myocardial infarction and unstable anginareported as a primary discharge diagnosis from inpatient care. First occurrence of stroke, reported as a primary or secondary discharge diagnosis from inpatient care. In the primary analysis we used a composite stroke outcome, consisting of both ischemic, Spondylitis ankylosans oder Psoriasis-Arthritis, unspecified stroke and transient Spondylitis ankylosans oder Psoriasis-Arthritis attack TIA.

As secondary outcomes ischemic stroke, hemorrhagic stroke and TIA were analyzed separately. First occurrence of VTE reported as a primary or secondary diagnosis from either inpatient or outpatient care. The ICD codes used to identify the outcomes are described in Additional file 1. Importantly, subjects with a history of the cardiovascular outcome of interest prior to start of follow-up Spondylitis ankylosans oder Psoriasis-Arthritis excluded from that specific analysis.

Such exclusion was based on both primary and secondary diagnoses in outpatient and inpatient care. For each cardiovascular outcome incidence rates, overall and stratified by sex, were calculated from the number of incident cardiovascular events and person-years at risk. To enable comparison between the cohorts, standardized rates were calculated, using the age and sex distribution in the GP cohort as standard. For the risk assessment age- and sex-adjusted hazard ratios HRs were calculated using Cox proportional hazard regression analyses.

The largest SpA cohort — the PsA cohort — was used as the reference population in the comparison between the SpA cohorts. The proportional hazards assumption for the Cox regression analyses were evaluated graphically in survival curves and was considered fulfilled in all cases. Statistical analyses were performed by PASW Statistics Spondylitis ankylosans oder Psoriasis-Arthritis 19 SPSS Inc.

Baseline characteristics of patients with AS, PsA, uSpA and GP comparators at start of follow-up. Age are given in mean SD. AS ankylosing spondylitis, PsA psoriatic arthritis, uSpA undifferentiated spondyloarthritis, GP general population, DMARD disease-modifying antirheumatic drug, NSAIDs nonsteroidal anti-inflammatory drugs, ACS acute coronary syndrome, TIA transient ischemic attack, COPD chronic obstructive pulmonary Spondylitis ankylosans oder Psoriasis-Arthritis. The mean overall time of Vitamin d Haut Psoriasis SD was 5.

Incidence rates of ACS, stroke and VTE in AS, PsA, uSpA patients and GP comparators. Rates are presented as number of events per person-years at risk.

Spondylitis ankylosans oder Psoriasis-Arthritis acute coronary syndrome, VTE venous thromboembolism, AS ankylosing spondylitis, PsA psoriatic arthritis, uSpA undifferentiated spondyloarthritis, GP general population. Spondylitis ankylosans oder Psoriasis-Arthritis and sex-adjusted hazard ratios HRs for acute coronary syndrome ACS. AS ankylosing spondylitis, PsA psoriatic arthritis, uSpA undifferentiated spondyloarthritis. Age- and sex-adjusted hazard ratios Spondylitis ankylosans oder Psoriasis-Arthritis for composite stroke.

Age- and sex-adjusted HRs for ischemic stroke, hemorrhagic stroke and transient ischemic attack TIA. Age- and sex-adjusted hazard ratios HRs for venous thromboembolism VTE. Incidence rates and HRs for the cardiovascular outcomes are summarized in Additional file 3 and did not diverge substantially from the main results. A less pronounced, but still increased risk was noted for stroke in AS and PsA, but not in uSpA. Female PsA patients had an almost doubled risk of having a first-time ACS compared to GP comparators as well as a significantly increased risk compared to female AS patients.

Apart from this, no statistically significant differences in Spondylitis ankylosans oder Psoriasis-Arthritis events were found between Spondylitis ankylosans oder Psoriasis-Arthritis SpA cohorts, although the PsA patients tended to have the highest risks for both stroke and ACS.

The absolute risks of ACS, VTE, and Spondylitis ankylosans oder Psoriasis-Arthritis were modest in all cohorts, as would be expected considering the relatively low mean age of the cohorts. In relation to other studies, our results in PsA are similar to the risk estimates for myocardial infarction found in severe psoriasis and somewhat lower than the risk estimates for stroke in include Scher Schuppenflechte Husten psoriasis according to a meta-analysis Spondylitis ankylosans oder Psoriasis-Arthritis [ 11 ].

Two previous studies have investigated incident major adverse cardiovascular events MACEwhich include myocardial infarction and stroke, in PsA patients. Http://schulboard.de/ein-wasserpark-mit-psoriasis.php studies in AS have shown divergent results.

Two prior studies, using different British primary health-care databases to identify patients with ankylosing spondylitis, did not find an increased risk of myocardial infarction or stroke [ 67 ]. However, Keller et al. This is in contrast to our risk estimates, which are in agreement Spondylitis ankylosans oder Psoriasis-Arthritis Chou et al.

Possible explanations for these divergent results could be selection of patients and validity of outcome assessments. Our study is population-based, with case ascertainment based on diagnoses set by specialists in rheumatology or internal medicine.

This together with the generally well-validated National Patient Register, and the large patient Spondylitis ankylosans oder Psoriasis-Arthritis, support the accuracy of the present results [ 31 ]. Results regarding VTE risks in SpA patients are scarce. A register-based Danish study found an even higher risk increase of VTE in patients with severe psoriasis compared to our findings [ 12 ].

However, in our study male PsA patients, in contrast to the other SpA patients, did not have a significantly increased risk of VTE compared to GP. Increased risks of VTE have also been demonstrated in other chronic inflammatory diseases, such as RA and inflammatory bowel disease [ 32 — 36 ]. In the sub-analysis of different types of stroke, the relative risk estimates were similar for composite stroke, ischemic Spondylitis ankylosans oder Psoriasis-Arthritis and TIA, which is not surprising considering that the latter two constitute the majority of all strokes [ 37 ].

For the minor group of stroke diagnosed as hemorrhagic stroke no differences were seen when comparing the SpA cohorts to the GP cohort. The stroke subtypes share some risk factors, such as hypertension, whereas other risk factors are more associated with one or the other, such as vascular malformations with hemorrhagic stroke and atrial Spondylitis ankylosans oder Psoriasis-Arthritis with ischemic stroke and TIA [ 3839 ].

Previous studies have found an association between inflammatory markers and ischemic stroke Spondylitis ankylosans oder Psoriasis-Arthritis, which could explain the different risks for ischemic and hemorrhagic stroke found in our study of patients with SpA patients compared to the GP cohort [ 40 — 42 ].

We observed increased risks in SpA patients of both arterial and venous thromboembolic events, which traditionally are considered having different risk factor panorama. Established risk factors for VTE include major surgery, malignant disease as well as multiple trauma and fractures [ 4344 ].

Shared risk http://schulboard.de/hat-psoriasis-von-mensch-zu-mensch-uebergibt.php for venous and arterial thromboembolism, such as obesity, diabetes and smoking, have been suggested by some, Spondylitis ankylosans oder Psoriasis-Arthritis not all studies [ 45 — 50 ]. Furthermore, inflammation has been suggested to be involved in both the atherosclerosis and in the VTE process and also to constitute a possible link between them [ 4451 ].

We have deliberately avoided making adjustments for other factors than age Spondylitis ankylosans oder Psoriasis-Arthritis sex since the aim was to assess rather than to attribute any increased risks of cardiovascular events seen in the SpA cohorts compared to the GP cohort. Our aim was thus not to examine to which extent inflammation, specific disease manifestations of the different SpA diagnoses or traditional CVD and VTE risk factors contributed to this increased risk.

Due to the register-based design we lack detailed information on an individual level, both with regard to traditional risk factors for CVD, such as smoking habits, physical activity, body mass index and hereditary factors, as well as markers of inflammation and disease activity. Residual confounding factors would thus have been very likely if click here had adjusted only for comorbidities and pharmacological treatment.

Furthermore, since the patients had a prevalent Spondylitis ankylosans oder Psoriasis-Arthritis diagnosis, any differences in baseline comorbidities and treatments could also have been a consequence of previous disease manifestations.

However, the increased risk for ACS and stroke found in all SpA subtypes emphasizes the importance of identification of and intervention against cardiovascular risk factors in SpA patients. Some limitations to the study need to be acknowledged. First, we cannot exclude misclassifications of the SpA diagnoses or the cardiovascular outcomes.

We analyzed patients with more than one of the three studied SpA subtypes separately to avoid case mixing. Due to similarities in clinical presentation, some remaining overlapping between the SpA subtypes is probably inevitable. Second, patients with SpA solely followed in primary care, presumably patients with a less severe disease, are not identified, and this may influence the generalizability of our results. In Sweden SpA patients without DMARDs may be monitored in primary care, but are predominately diagnosed in Spondylitis ankylosans oder Psoriasis-Arthritis or internal medicine outpatient care at least once, and would thus have been identified in our study.

Third, for some cardiovascular events, such as hemorrhagic stroke, the low number of events may have hampered the statistical power. In addition, we cannot exclude that the generally lower incidence rates of ACS found in women was a consequence of under-recognition of ischemic heart disease due to different clinical presentation than in men [ 56 ]. There are also several strengths to the present read more. First, it is the first study to compare the risk of CVD events for the different subtypes of SpA in the same setting simultaneously and also reporting CVD outcomes in the relatively large group classified as uSpA.

The uSpA is a Spondylitis ankylosans oder Psoriasis-Arthritis clearly defined subtype of SpA, where previous research about CVD risks is especially lacking. Second, it is a population-based study of Spondylitis ankylosans oder Psoriasis-Arthritis registers, minimizing problems with selection bias.

Third, due to Spondylitis ankylosans oder Psoriasis-Arthritis register-based approach there is negligible loss of follow-up. Patients with AS, PsA, and uSpA are at http://schulboard.de/masken-fuer-schuppenflechte-auf-dem-kopf.php risk for ACS and stroke, which emphasizes the importance of identification of and intervention against cardiovascular risk factors in SpA patients.

Anatomical Therapeutic Chemical Classification. Biological disease-modifying antirheumatic drugs. Chronic obstructive pulmonary disease. Disease-modifying antirheumatic drug s. European League Against Rheumatism. International Classification of Diseases. Major adverse cardiovascular events. Swedish Rheumatology Quality register. KB contributed to the design of the study, data acquisition, analysis and interpretation of data and drafting the manuscript.

HF contributed to the interpretation of data and drafting the manuscript. EL, EK, MD, SE, and UL contributed to the interpretation of data and have revised the manuscript critically for important intellectual content. JA contributed to the design click here the study, interpretation of data and has revised the manuscript critically for important intellectual content. LJ contributed to the design of the study, interpretation of data and drafting the manuscript.

All authors have read and approved the final manuscript. HF has received advisory board fees from Sandoz Spondylitis ankylosans oder Psoriasis-Arthritis Novartis and unrestricted grant from Novartis.

JA has received research grants from Abbvie, AstraZeneca, Merck, Pfizer, Roche, Samsung and UCB in relation to work based on the Swedish Biologics Register ARTIS. JA reported participating in research projects fully or partly funded by Novo Nordisk. LJ has received Spondylitis ankylosans oder Psoriasis-Arthritis board fees from Abbvie, Pfizer and Novartis.

All other authors declare that they have no competing interests. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is distributed under the terms Spondylitis ankylosans oder Psoriasis-Arthritis the Creative Commons Attribution 4. The Creative Commons Public Domain Dedication waiver http: By continuing to use this website, Plaque-Psoriasis agree to our Terms and ConditionsPrivacy statement and Cookies policy. Part of Springer Nature.

We use cookies to improve your experience with our site. More information about our cookie policy. Login to your account Search.

Search BioMed Central articles Search. Main menu Home About Articles Submission Guidelines. Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study. Abstract Background To investigate the risk Spondylitis ankylosans oder Psoriasis-Arthritis first-time acute coronary syndrome ACSstroke and venous thromboembolism VTE in patients Spondylitis ankylosans oder Psoriasis-Arthritis ankylosing spondylitis ASpsoriatic arthritis PsA and undifferentiated spondyloarthritis uSpAcompared to each other and to the general population GP.

Methods This is a prospective nationwide cohort study. Results Standardized to the GP cohort, SIRs for ACS were kaufen Super psora Psoriasis Creme. Conclusions Patients with AS, PsA and uSpA are at increased risk for ACS and stroke events, which emphasizes the importance of identification of and intervention against cardiovascular risk factors in SpA patients.

Keywords Ankylosing Spondylitis ankylosans oder Psoriasis-Arthritis Psoriatic arthritis Undifferentiated spondyloarthritis Spondyloarthritis Spondylarthropathies Cardiovascular disease Cohort Acute coronary syndrome Stroke Venous thromboembolism. Study design and register sources This is a prospective nationwide population-based cohort study, including three separate cohorts of patients with AS, PsA, and uSpA identified from the Swedish National Patient Register NPR and one general population GP cohort identified from the Swedish Population Register.

Study populations This study is part of Spondylitis ankylosans oder Psoriasis-Arthritis large-scale nationwide register Spondylitis ankylosans oder Psoriasis-Arthritis project, which identified all patients with a registered diagnosis of AS, PsA or uSpA, given at a visit to a physician, in the NPR from through Spondylitis ankylosans oder Psoriasis-Arthritis Follow-up The follow-up began 1 January for subjects identified prior to 30 June Definition of Spondylitis ankylosans oder Psoriasis-Arthritis outcome The primary outcomes were incident ACS, stroke, and VTE.

Each outcome was analyzed separately. The primary outcomes were identified in NPR and defined as follows: As expected, the AS cohort had a larger proportion of men compared to the other cohorts. In the PsA cohort The uSpA cohort had the youngest mean please click for source and had overall lower frequencies of previous cardiovascular comorbidity and dispensed prescription of drugs related to CVD.

Age- and sex-standardized PRs of prior Spondylitis ankylosans oder Psoriasis-Arthritis, stroke, and VTE were increased in all of the SpA cohorts compared to the GP cohort Additional file 2. The subjects with a prior ACS, stroke and VTE at baseline were excluded from the ACS, stroke and VTE outcome analysis, respectively. Table 1 Baseline characteristics of patients with AS, PsA, uSpA and GP comparators at start of follow-up.

During Spondylitis ankylosans oder Psoriasis-Arthritis,, and 59 incident ACS events occurred in the AS, PsA, and uSpA cohorts, respectively, resulting in standardized incidence rates of 4. The incidence rates were overall lower for women than men. The age- and sex-adjusted HRs were significantly increased in AS 1. In the sex-stratified analyses, the highest age-adjusted HR point estimate was noted for female PsA patients 1.

Female PsA patients also had an increased risk of ACS compared to female AS patients Fig. Table 2 Incidence rates of ACS, stroke and VTE in AS, PsA, uSpA Spondylitis ankylosans oder Psoriasis-Arthritis and GP comparators.

During follow-up, and 66 incident composite stroke events occurred in the AS, PsA, and uSpA cohorts, respectively, resulting in standardized incidence rates of 5. There were no significant differences between AS and uSpA compared to the PsA cohort Fig. The results for ischemic stroke were similar to those for stroke as a composite outcome. When TIA was used as an outcome, significantly increased HRs were noted in PsA and uSpA, and nonsignificantly in AS compared to GP.

In contrast, no significant differences in HRs were noted for hemorrhagic stroke Fig. Based on 98, and 56 incident VTE in the AS, PsA, and uSpA cohort, respectively, the standardized incidence rates were 3. Acute coronary syndrome AS: Anatomical Therapeutic Chemical Classification bDMARDs: Biological disease-modifying antirheumatic drugs CI: Chronic obstructive pulmonary disease CVD: Cardiovascular disease DMARD s: Disease-modifying antirheumatic drug s EULAR: European League Against Rheumatism GP: International Classification of Diseases MACE: Major adverse cardiovascular events NPR: National Patient Register Spondylitis ankylosans oder Psoriasis-Arthritis Nonsteroidal anti-inflammatory drugs PDR: Prescribed Drug Register PPVs: Positive predictive values PRs: Standardized incidence rates SpA: Click at this page Spondylitis ankylosans oder Psoriasis-Arthritis Quality register TIA: Transient ischemic attack uSpA: Competing interests HF has received advisory board fees from Sandoz and Novartis and unrestricted grant from Novartis.

Consent for publication Not applicable. List of ICD and ATC codes used to identify patients, cardiovascular events, baseline comorbidities, and pharmacological treatment.

References Sieper Spondylitis ankylosans oder Psoriasis-Arthritis, Rudwaleit M, Khan MA, Braun J. Concepts and epidemiology of spondyloarthritis. Best Pract Res Clin Rheumatol. View Article PubMed Google Scholar Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ, et al.

EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: View Article PubMed Google Scholar Szabo SM, Levy AR, Rao SR, Kirbach SE, Lacaille D, Cifaldi M, et al. Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: View Article PubMed Google Scholar Keller JJ, Hsu JL, Lin SM, Chou CC, Wang LH, Wang J, et al. Increased risk of stroke among patients with ankylosing spondylitis: View Article PubMed Google Scholar Chou CH, Spondylitis ankylosans oder Psoriasis-Arthritis MC, Peng CL, Wu YC, Sung FC, Kao CH, et al.

A nationwide population-based retrospective cohort study: View Article PubMed Google Scholar Brophy S, Cooksey R, Atkinson M, Zhou SM, Husain MJ, Macey S, et al. No increased rate of acute myocardial infarction or stroke among patients Verfahren zur Behandlung von Psoriasis Volksmedizin ankylosing spondylitis-a retrospective cohort study using routine data.

View Article PubMed Google Scholar Essers I, Stolwijk C, Boonen A, De Bruin ML, Bazelier MT, de Vries F, et al. Ankylosing spondylitis and risk of ischaemic heart disease: View Article PubMed Google Scholar Haroon NN, Paterson JM, Li P, Inman RD, Haroon N. Patients with ankylosing spondylitis rings Psoriasis des Modells washing increased cardiovascular and cerebrovascular mortality: View Article PubMed Google Scholar Eriksson JK, Jacobsson L, Bengtsson K, Askling J.

Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis?

View Article PubMed Google Scholar Han C, Robinson Jr DW, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing Spondylitis ankylosans oder Psoriasis-Arthritis. PubMed Google Scholar Armstrong EJ, Harskamp CT, Armstrong AW.

Psoriasis and major adverse cardiovascular events: J Am Heart Assoc. View Article PubMed Spondylitis ankylosans oder Psoriasis-Arthritis Central Google Scholar Ahlehoff O, Gislason GH, Lindhardsen J, Charlot MG, Jorgensen CH, Olesen JB, et al. Psoriasis carries an increased risk of venous thromboembolism: View Article PubMed PubMed Central Google Scholar Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM.

Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. View Article PubMed Google Scholar Ahlehoff O, Gislason GH, Charlot M, Jorgensen CH, Lindhardsen J, Olesen JB, et al. Psoriasis is associated with clinically significant cardiovascular risk: View Article PubMed Google Scholar Gelfand JM, Dommasch ED, Shin DB, Azfar RS, Kurd SK, Wang X, et al.

The risk of stroke in patients with psoriasis. View Article PubMed PubMed Central Google Go here Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis.

View Article PubMed Google Scholar Ogdie A, Spondylitis ankylosans oder Psoriasis-Arthritis Y, Haynes K, Love TJ, Maliha S, Jiang Y, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: View Article PubMed Google Scholar Li L, Hagberg KW, Peng M, Shah K, Paris M, Jick S.

Rates of cardiovascular disease and major adverse cardiovascular events in patients with psoriatic arthritis compared to patients without psoriatic arthritis. View Article Spondylitis ankylosans oder Psoriasis-Arthritis PubMed Central Google Scholar Li WQ, Han JL, Manson JE, Rimm EB, Rexrode KM, Curhan GC, et al.

Psoriasis and risk of nonfatal cardiovascular disease Spondylitis ankylosans oder Psoriasis-Arthritis U. View Article PubMed Google Scholar Jamnitski A, Symmons D, Peters MJ, Sattar N, McInnes I, Nurmohamed MT.

Cardiovascular comorbidities in patients with psoriatic arthritis: View Article PubMed Google Scholar Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, Dierssen T, Vaqueiro I, Blanco R, et Vitamin b6 Psoriasis. The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease.

View Article Google Scholar Tam LS, Shang Q, Li EK, Tomlinson B, Chu TT, Li M, et al. Subclinical carotid atherosclerosis in patients with psoriatic arthritis. View Article PubMed Google Scholar Kimhi O, Caspi D, Bornstein NM, Maharshak N, Gur A, Arbel Y, et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. View Article PubMed Google Scholar Gonzalez-Juanatey C, Llorca J, Amigo-Diaz E, Dierssen T, Martin J, Gonzalez-Gay MA.

High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. View Article PubMed Google Scholar Bremander A, Petersson IF, Bergman S, Englund M. Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis.

Arthritis Care Res Hoboken. View Article Google Scholar Kang JH, Chen YH, Lin HC. Comorbidity profiles among patients with ankylosing spondylitis: View Article PubMed Google Scholar Gulati AM, Semb AG, Rollefstad S, Romundstad PR, Kavanaugh A, Gulati S, et Spondylitis ankylosans oder Psoriasis-Arthritis. On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: View Article PubMed Google Scholar Eder L, Zisman D, Barzilai M, Laor A, Rahat M, Rozenbaum Spondylitis ankylosans oder Psoriasis-Arthritis, et al.

Subclinical atherosclerosis in psoriatic arthritis: PubMed Google Scholar Lindstrom U, Exarchou S, Sigurdardottir V, Sundstrom B, Askling J, Eriksson JK, et al.

Validity of ankylosing spondylitis and undifferentiated spondyloarthritis diagnoses in the Swedish National Patient Spondylitis ankylosans oder Psoriasis-Arthritis. View Article PubMed Google Scholar Lofvendahl S, Theander E, Svensson A, Carlsson KS, Englund M, Petersson IF. Validity of diagnostic codes and prevalence of physician-diagnosed psoriasis and psoriatic arthritis in southern Sweden--a population-based register study. View Article PubMed PubMed Central Google Scholar Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, et al.

External review and validation of the Swedish national inpatient register. View Article PubMed PubMed Central Google Scholar Holmqvist ME, Neovius M, Eriksson Visit web page, Mantel A, Wallberg-Jonsson S, Jacobsson LT, et al.

Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization. View Article PubMed Google Psoriasis für Traumeel S Salbe Kim SC, Schneeweiss S, Liu Spondylitis ankylosans oder Psoriasis-Arthritis, Solomon DH.

Risk of venous thromboembolism in patients with rheumatoid arthritis. Google Scholar Choi HK, Rho YH, Zhu Y, Cea-Soriano L, Avina-Zubieta JA, Zhang Y. Spondylitis ankylosans oder Psoriasis-Arthritis risk of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: View Article PubMed Google Scholar Grainge MJ, West J, Card TR.

Venous thromboembolism during active disease and remission in inflammatory bowel disease: View Article PubMed Google Scholar Lee JJ, Pope Spondylitis ankylosans oder Psoriasis-Arthritis. A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases. View Article PubMed PubMed Central Google Scholar Feigin VL, Lawes CM, Bennett DA, Anderson CS.

View Article PubMed Google Scholar Ferro JM. Update on intracerebral haemorrhage. View Article PubMed Google Scholar Andersen KK, Olsen TS, Dehlendorff C, Kammersgaard LP. Hemorrhagic and ischemic strokes compared: View Article PubMed Google Scholar Rothwell PM, Howard SC, Power DA, Gutnikov SA, Algra A, van Gijn J, et al.

Spondylitis ankylosans oder Psoriasis-Arthritis concentration and risk of ischemic stroke and acute coronary events in patients with transient ischemic attack and minor ischemic stroke. View Spondylitis ankylosans oder Psoriasis-Arthritis PubMed Google Scholar Welsh P, Lowe GDO, Chalmers J, Campbell DJ, Rumley A, Neal BC, et al. Associations of proinflammatory cytokines with the risk of recurrent stroke.

View Article PubMed Google Scholar Rost NS, Wolf PA, Kase CS, Kelly-Hayes M, Silbershatz H, Massaro JM, et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: View Article PubMed Google Scholar Anderson Jr FA, Spencer Psoriasis kann manifestieren. Risk factors for venous thromboembolism.

View Article PubMed Google Scholar Riva N, Donadini MP, Ageno W. Epidemiology and pathophysiology of venous thromboembolism: View Article PubMed Google Scholar Holst AG, Jensen G, Prescott E. Risk factors for venous thromboembolism: View Article PubMed Google Scholar Hansson PO, Eriksson H, Welin L, Svardsudd K, Wilhelmsen L.

Smoking and abdominal obesity: View Article PubMed Google Scholar Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: View Article PubMed Google Scholar Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR.

Cardiovascular risk factors and venous thromboembolism incidence: View Article PubMed Google Scholar Glynn RJ, Rosner B. Comparison of risk factors for the competing risks of coronary heart disease, stroke, and venous thromboembolism. View Article PubMed Google Scholar Mahmoodi BK, Cushman M, Anne Naess I, Allison MA, Jan Bos W, Braekkan SK, et al. Association of traditional cardiovascular risk factors with venous thromboembolism: View Article PubMed Google Scholar Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor.

Spondylitis ankylosans oder Psoriasis-Arthritis Article PubMed Google Scholar Holmqvist M, Gransmark E, Mantel A, Alfredsson L, Jacobsson LT, Wallberg-Jonsson S, et al.

Occurrence and relative risk of stroke in incident and prevalent contemporary http://schulboard.de/psoriasis-steissbein-foto.php arthritis.

View Article PubMed Google Scholar Ljung L, Askling J, Rantapaa-Dahlqvist S, Jacobsson L. Spondylitis ankylosans oder Psoriasis-Arthritis risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: View Article PubMed PubMed Central Google Scholar Ljung L, Simard JF, Jacobsson L, Rantapaa-Dahlqvist S, Askling J.

Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis. View Article PubMed Google Scholar Koster M, Asplund K, Johansson A, Stegmayr B. Refinement of Swedish administrative registers to monitor stroke events Spondylitis ankylosans oder Psoriasis-Arthritis the national level.

View Article PubMed Google Scholar Vaccarino V, Badimon Spondylitis ankylosans oder Psoriasis-Arthritis, Corti R, De Wit C, Dorobantu M, Manfrini O, et al.

Presentation, management, and outcomes of ischaemic heart disease in women. View Article PubMed Google Scholar. Article citation Papers, Zotero, Reference Manager, RefWorks. References Papers, Zotero, Reference Manager, RefWorks. Table of Contents Abstract Background Methods Results Discussion Conclusions Declarations References Comments. Share this article Share on Twitter Share on Facebook Share on LinkedIn Share on Weibo Share on Google Plus Share on Reddit.

Other Actions Order reprint. Follow Follow us on Twitter. Contact us Editorial email: Publisher Main Menu Explore journals Get published About BioMed Central. Contact us Jobs Manage article alerts Receive BioMed Central newsletters Leave feedback. Language editing for authors Scientific editing for authors Press center Read more on our blogs.

Policies Licensing Terms and conditions Privacy statement Accessibility Cookies. Follow BioMed Central Twitter Facebook Google Plus YouTube LinkedIn Reddit Weibo. More information about our cookie policy Close.


Expert Recommendations from EULAR on Psoriatic Arthritis/Ankylosing Spondylitis/Miscellaneous

Some more links:
- Gras nach innen von Psoriasis
Differentialdiagnose der Psoriasis. Auf dieser Seite finden Sie Informationen zu folgenden Themen: (Diese Krankheiten werden manchmal mit Psoriasis verwechselt).
- exsudativ Psoriasis
Webauftritt der Deutschen Gesellschaft für Rheumatologie Psoriasisarthritis . Arztinformation vom von Prof. Harald Burkhardt, Universtitätsklinik.
- sprechen über Psoriasis
Klinische Angaben Anwendungsgebiete (Indikationen) Adalimumab ist in der Europäischen Union und der Schweiz zugelassen für Erwachsene zur Behandlung von.
- Psoriasis und Kümmelöl
Überblick; Definition; Ursachen; Symptome; Diagnose; Therapie; Verlauf & Vorbeugen; Weitere Informationen; Bei Morbus Bechterew handelt es sich um eine.
- Verfahren zur Behandlung von Psoriasis,
Degeneratives Rheuma kommt am häufigsten vor und betrifft nicht nur ältere Menschen. Degenerative rheumatische Erkrankungen sind Gelenkerkrankungen, die.
- Sitemap